BRAND

Name No. For Patients with Purpose
BRAND 23-11

Non-Small Cell Lung Cancer

The main purpose of this study is see if EBC(Exhaled Breath Condensate) can be used to check for biomarkers which are associated with a radiologic response to chemoimmunotherapy for patients with advanced NSCLC


IMMUNO FERTILITY

Name No. For Patients with Purpose
IMMUNO FERTILITY 22-22

Patients of Childbearing Potential who receive ICIs(Immune checkpoint inhibitors) for Cancer

This study will use a number of tests to assess reproductive parameters in patients 1-2 years after they have received ICI therapy to observe the effect that ICI therapy may have on a patient’s fertility.


Krystal-7

Name No. For Patients with Purpose
Krystal-7 22-07

Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

This Phase 2 study will evaluate the efficacy and safety of MRTX849 on its own and in combination with pembrolizumab.


KRYSTAL-12

Name No. For Patients with Purpose
KRYSTAL-12 21-13

previously treated metastatic NSCLC with a KRAS G12C mutation.

To evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.


CA224-104 (RELATIVITY)

Name No. For Patients with Purpose
CA224-104 (RELATIVITY) 21-12

Participants with previously untreated Stage IV Non-Small Cell Lung Cancer.

The objective of the trial is to confirm the dose safety of combination relatlimab and nivolumab plus chemo and to compare the progression free survival for patients with untreated stage IV Non-Small Cell Lung Cancer or Recurrent Non-small Cell Lung Cancer.


AcceleRET-Lung

Name No. For Patients with Purpose
AcceleRET-Lung 20-21

This clinical trial is recruiting people with non-small cell lung cancer (NSCLC) that cannot be removed through surgery or that has spread to other parts of the body.

AcceleRET-Lung: A clinical trial to compare a medicine called pralsetinib with standard-of-care chemotherapy treatments in people with non-small cell lung cancer (NSCLC).


SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours

Name No. For Patients with Purpose
SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours 18-33

inoperable, early stage, high-risk ultracentrally located lung tumours.

The purpose of the study is to determine the safety of the radiation therapy treatment regimen in terms of side effects experienced within one year after treatment which are related to the radiation therapy.


AbbVie M14-239

Name No. For Patients with Purpose
AbbVie M14-239 18-49

locally advanced or metastatic non-small cell lung cancer previously treated with systemic cytotoxic therapy (or ineligible), and an immune checkpoint inhibitor (as monotherapy or in combination with systemic cytotoxic chemotherapy, or ineligible)

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2).